Background 20 Adipose-derived mesenchymal stem cells (ADSCs) have emerged as a promising therapeutic 21 modality for cellular therapy because of their rapid proliferation and potent cellular activity 33 exploited.
compared to conventional bone marrow-derived mesenchymal stem cells (MSCs). Cosmetic 23 lipoaspirates provide an easily obtainable source of ADSCs. Cryopreservation facilitates their 24 clinical application due to increased transportability and pooling of sufficient numbers of cells. 25 However, proper cryopreservation techniques have not been established yet.
26
Methods 27 We evaluated the post-thaw viability and ADSC functions after cryopreservation with three 28 cryoprotectants (serum containing 10% dimethylsulfoxide (DMSO), serum-free: CP-1 TM , 29 DMSO-free: SCB-DF TM ) at two temperature (−80°C, −150°C) and two cell densities: (1 × 10 6 , 30 7 × 10 6 cells/mL) for up to 18 months using cryovials. After determining optimal conditions, we 31 also tested if large quantities of ADSCs remained viable after 18 months of cryopreservation in 32 a 100-mL cryobag. Rate-controlled freezing methods or liquid nitrogen storage were not Human ADSCs were plated onto T75 flasks and cultured until cells reached a enough number 91 for cryopreservation. Prior to freezing, ADSCs (80% confluency) were detached from the flask 92 walls with trypsin/EDTA, and viable cells were counted with the trypan blue exclusion method. 93 After centrifugation, supernatant was removed completely, and cells were resuspended in one of 94 three types of freezing medium: 10% DMSO in FBS (hereafter abbreviated as DMSO), CP-1, or 95 SCB-DF, at two different cell densities: 1 × 10 6 or 7 × 10 6 cells/mL in 0.2-mL cryopreservation 96 vials (0.1 mL/vial), and then stored in a −80°C deep freezer or a −150°C ultra-low temperature 97 freezer for 3, 9, or 18 months. In another setting, cell suspensions of ADSCs were prepared at 7 98 approximately 1 × 10 6 cells/mL in a total volume of 50 mL and then placed in 100-mL cryobags 99 (Terumo, Tokyo, Japan). The cryobags containing ADSCs were directly placed into a −150°C 100 ultra-deep freezer and stored for 24 months.
102
Cell thawing and cell recovery rate 103 Frozen cryovials or cryobags were quickly thawed in a circulating 37°C water bath by gently 104 shaking and agitating until the ice mass disappeared. Then, the cell suspension from cryovials 105 was washed with culture medium once, and recovery rates were evaluated with the trypan blue isotype-matched antibodies. The multilineage potential of ADSCs was confirmed as described 122 elsewhere (9). Briefly, freshly established ADSCs and ADSCs after the freeze-thawing process 123 were exposed to adipogenic formulas (R&D Systems, Minneapolis, MN) for 14 days or to 124 osteogenic formulas (R&D Systems) for 21 days. Accumulation of intracellular lipid-rich 125 vacuoles resulting from adipogenic differentiation was assessed by Sudan III staining. 126 Osteogenic differentiation was specifically evaluated by von Kossa staining to detect calcium week, and proliferation of floating cells was assessed in three randomly selected microscopic 140 fields (200×). At the end of the coculture, the progenitor content of each well was assayed with 141 methylcellulose colony assays as described previously (11) Redmond, WA). All statistical tests were two-sided. 3, 9, or 18 months. The stored cells were rapidly thawed in a water bath at 37°C, and viable 162 cells were counted using the trypan blue exclusion method under a microscope. Cells in all 163 subgroups showed minimal cell aggregation.
164
When stored at −80°C ( Figure 1A) , the post-thaw recovery rate of human ADSCs was stable 165 after 9 months, but rapidly and significantly decreased after 18 months. None of the CPAs or 166 cell densities tested prevented the decrease in the post-thaw recovery rate at 18 months. 167 However, DMSO, CP-1, and storage at high cell density (7 × 10 6 cells/mL) were superior to 168 SCB-DF and storage at low cell density (1 × 10 6 cells/mL).
169
When stored at −150°C ( Figure 1B) , the post-thaw recovery rate of human ADSCs decreased 170 over time, similar to storage at −80°C. However, cell viability was better in all subgroups at 18 171 months compared to storage at −80°C. Additionally, storage at the high cell density (7 × 10 6 172 cells/mL) maintained greater viability of ADSCs than storage at the low cell density (1 × 10 6 173 cells/mL) in each CPA. Minimal cell damage was observed in cells stored at high cell density (7 174 × 10 6 cells/mL) with DMSO or CP-1, even after 18 months.
12 Figure 1 . Post-thaw recovery rate of human ADSCs in various freezing conditions. Prior to 177 cryopreservation, human ADSCs were suspended in three different CPAs: DMSO (white 178 columns), CP-1 (black columns), or SCB-DF (gray columns), at two different cell densities: 1 × 179 10 6 or 7 × 10 6 cells/mL in 0.2-mL cryopreservation vials (0.1 mL/vial), and then stored in a 180 −80°C deep freezer (A) or a −150°C ultra-low temperature freezer (B) for 3, 9, or 18 months.
181
The stored cells were rapidly thawed in a water bath at 37°C, and viable cells were counted with 182 the trypan blue exclusion method. The percent post-thaw viable cells was calculated as follows:
183 viable cells after thawing (cells/mL)/viable cells before cryopreservation (cells/mL) × 100 (%).
184
The results shown reflect the mean (± SD) of triplicate determinations. The asterisks denote 185 statistical significance (**P < 0.01; *P < 0.05).
187
These data suggest that optimal storage conditions for human ADSCs are cryopreservation in 188 DMSO or CP-1, low temperature (−150°C), and high cell density (7 × 10 6 cells/mL). ADSCs 189 can be safely cryopreserved for at least 18 months in such a condition. The hematopoiesis-supporting ability of human ADSCs 192 is not affected by long-term cryopreservation 193 To assess the quality of human ADSCs after long-term cryopreservation, we focused on the Figure 2B ), consistent with our previous 205 report (12). We found no significant difference in the proportion of each lineage or the total 206 number of colonies among the four subgroups ( Figure 2B ). conditions: in CP-1 (approximately 1 × 10 6 cells/mL in a total volume of 50 mL) at −150°C.
214
After 24 months of cryopreservation, cells were quickly thawed in a water bath at 37°C. The 215 viability of cells was 91.9 ± 3.9% (mean ± SD) with minimal cell aggregates. The cells showed 216 no morphological changes and propagated well, similar to fresh ADSCs. FACS analysis showed 217 that post-thawed human ADSCs were positive for CD29, CD73, CD105, CD90, and 218 HLA-ABC, and negative for CD45, CD34, CD14, and HLA-DR ( Figure 2C ). These phenotypes 219 met the minimal criteria of MSCs as defined by the International Society for Cell Therapy (13).
220
To confirm the differentiation ability of the frozen and thawed human ADSCs, cells were 221 exposed to adipogenic formulas for 14 days or osteogenic formulas for 21 days. Accumulation 222 of intracellular lipid-rich vacuoles resulting from adipogenic differentiation was assessed with Sudan III staining. Osteogenic differentiation was specifically evaluated with von Kossa 224 staining to detect calcium deposition. Lipid drops were clearly detected inside cells, but calcium 225 deposition was minimally observed (data not shown). In this report, we evaluated the post-thaw viability and ADSC functions after cryopreservation 253 with three different cryoprotectants (serum containing 10% DMSO, serum-free, or DMSO-and 254 serum-free), at two different cell densities: 1 × 10 6 or 7 × 10 6 cells/mL, at two different 255 temperatures (−80°C and −150°C) for up to 18 months. We did not exploit rate-controlled 256 freezing methods or liquid nitrogen storage. We found that the following conditions were 257 optimal: higher cell density (7 × 10 6 cells/mL), usage of DMSO, and lower storage temperature 258 (−150°C) ( Figure 1A and 1B) . However, even suboptimal conditions (−80°C, 1 × 10 6 cells/mL, 259 no DMSO) in which cells were stored up to 9 months produced a post-thaw recovery rate >80% 260 ( Figure 1A and 1B) . These facts suggest that rate-controlled freezing methods or liquid nitrogen 261 storage are not necessary for cryopreservation of ADSCs over a short-to mid-term period.
262
Serum containing 10% DMSO has been used for years as a standard cryoprotectant agent, 263 because DMSO can penetrate into cells and prevent the formation of intracellular ice crystals 264 and subsequent membrane rupture. Our current experiments showed that post-thaw cell 265 recovery was significantly low in ADSCs cryopreserved with SCB-DF ( Figure 1A and 1B) , 266 suggesting an important role for DMSO. However, DMSO, when infused into the body, exerts 267 side effects such as nausea, emesis, chills, rigors, and cardiovascular events in a dose-dependent 268 manner (5-7). CP-1 is a 25% human serum albumin solution that is mixed just before use and 269 added to an equal volume of cell suspension, yielding a final freezing medium with 5% DMSO, 270 which has low risk for side effects. In Japan, CP-1 has been clinically used for cryopreservation 271 of HSCs for decades with few side effects reported (14, 15). Thus, CP-1 may be a safe, 272 easy-to-prepare, low-cost cryopreservation medium for ADSCs.
273
Freezing cells and thawing cryopreserved cells properly is crucial to the viability and 274 functionality of the cells. Freezing and thawing a large number of cells, which is imperative for 275 clinical application, in cryobags takes longer compared to cryovials. However, the viability of 276 human ADSCs cryopreserved in cryobags at −150°C for 24 months was over 90% with minimal 277 cell clumps. The morphology, growth rate, surface antigen profiles, and adipogenic 278 differentiation, but not osteogenic differentiation, of these cells were the same as those of fresh 279 ADSCs. The osteogenic potential of ADSCs is inferior to that of BMSCs (16), and the 280 cryopreservation process decreases the osteogenic differentiation ability of ADSCs (17, 18).
281
Little was known about how long-term cryopreservation affects the hematopoietic-supporting 282 ability of ADSCs, one of the major features of ADSCs (19). Here, we show that both 283 cryopreserved and fresh ADSCs generated almost equal numbers of granulocytes and progenitor 284 cells from human HSCs using in vitro coculture and progenitor assays ( Figure 2B ), even though 285 the cell recovery rates of ADSCs stored with SCB-DF were lower compared with those with 286 DMSO or CP-1 ( Figure 1A and 1B) . These facts clearly suggest that cryopreservation can 287 perturb the ability of osteogenic differentiation of ADSCs but not the hematopoietic-supporting 288 ability. 289 Together, these observations provide helpful information about safe, cost-effective 290 cryopreservation of ADSCs that could be used in the clinical setting. 
